-
1
المؤلفون: Motzer, R, Alekseev, B, Rha, SY, Porta, C, Eto, M, Powles, T, Grunwald, V, Hutson, TE, Kopyltsov, E, Mendez-Vidal, MJ, Kozlov, V, Alyasova, A, Hong, SH, Kapoor, A, Gordoa, TA, Merchan, JR, Winquist, E, Maroto, P, Goh, JC, Kim, M, Gurney, H, Patel, V, Peer, A, Procopio, G, Takagi, T, Melichar, B, Rolland, F, De Giorgi, U, Wong, S, Bedke, J, Schmidinger, M, Dutcus, CE, Smith, AD, Dutta, L, Mody, K, Perini, RF, Xing, DY, Choueiri, TK, CLEAR Trial Investigators
المصدر: NEW ENGLAND JOURNAL OF MEDICINE
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instnameمصطلحات موضوعية: Oncology, Male, Programmed Cell Death 1 Receptor, Medizin, Pembrolizumab, 030204 cardiovascular system & hematology, urologic and male genital diseases, chemistry.chemical_compound, 0302 clinical medicine, Renal cell carcinoma, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, 80 and over, Sunitinib, Medicine, 030212 general & internal medicine, Humanized, Aged, 80 and over, General Medicine, Middle Aged, female genital diseases and pregnancy complications, Kidney Neoplasms, Progression-Free Survival, Quinolines, Female, Lenvatinib, medicine.drug, Adult, medicine.medical_specialty, Antineoplastic Agents, Antibodies, Monoclonal, Humanized, Antibodies, 03 medical and health sciences, Internal medicine, Carcinoma, Humans, Progression-free survival, Everolimus, Carcinoma, Renal Cell, Protein Kinase Inhibitors, Aged, business.industry, Phenylurea Compounds, Renal Cell, medicine.disease, Survival Analysis, chemistry, business
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0334f0faf7037f77f5c4cb15439bd9c2Test
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=4803Test -
2
المؤلفون: Koji Kawai, Satoshi Nagamori, Katherine M Bell-McGuinn, Cristiano Ferrario, Wen Pin Su, Isabel Syndikus, Aude Flechon, Georgios Gakis, Timothy Dudley Clay, Leticia Vazquez Cortés, Ronald de Wit, Florence Joly, Bozena Sikora-Kupis, Sergio Bracarda, Astra M. Liepa, Annemie Rutten, Daniel P. Petrylak, Su Peng Yeh, Annamaria Zimmermann, Sameera R. Wijayawardana, Mutsushi Kawakita, Siobhan Ng, Thean Hsiang Tan, Chikara Ohyama, Yu Jung Kim, Yuriy Golovko, Dimitrios Mavroudis, Jian Ri Li, Reinoud J. B. Blaisse, Mustafa Erman, Francesca Russo, Catherine Becht, Anghel Adrian Udrea, Robert Huddart, Syed A. Hussain, Fransiscus L.G. Erdkamp, Satoshi Fukasawa, Francesco Massari, Motohide Uemura, Boris Alekseev, Irfan Cicin, Se Hoon Park, Marcello Tucci, Lajos Géczi, Maureen J.B. Aarts, Yu Li Su, Fumimasa Fukuta, Hyo Jin Lee, Wolfgang Schultze-Seemann, Alexandra Drakaki, Hakan Harputluoglu, Xavier Garcia del Muro, Santhanam Sundar, Avivit Peer, Herlinde Dumez, William E. Lawler, Juan Ignacio Delgado Mignorance, Naveed Sarwar, Jeanny B. Aragon-Ching, Benjamin T. Herms, Fredrik Laestadius, Nobuaki Matsubara, Ivan Sinielnikov, Cora N. Sternberg, Hiroyuki Nishiyama, Piotr Tomczak, Brigitte Laguerre, Rebecca R. Hozak, Vasilis Karavasilis, Christina A. Schwentner, Hiroyuki Tsunemori, Masayoshi Nagata, Igor Bondarenko, Andrea Necchi, Yen Chuan Ou, Scott T. Tagawa, Constance Thibault, Richard A. Walgren, Akira Yokomizo, Evan Y. Yu, Alejo Rodriguez-Vida, Sufia Safina, Ulka N. Vaishampayan, János Révész, Aristotelis Bamias, Jae-Lyun Lee, Chien Liang Lin, Thomas W. Flaig, Roman Fomkin, Petr Alexandrovich Karlov, Joanna Wojcik-Tomaszewska, Junichi Inokuchi, Wataru Obara, Haralambos Kalofonos, John D. Hainsworth, Marc-Oliver Grimm, Thomas Eugene Lowe, Pablo Gajate Borau, Simon J. Crabb, Lisa Sengeloev, Junji Yonese, Simon Chowdhury, Elizabeth Jane Hovey, Daniel Castellano, Peter Istvan Acs, Chia-Chi Lin, Claudia Lorena Urzua Flores, Jean-Pascal Machiels, Kim N. Chi, Takahiro Osawa, Nobuo Shinohara, Daniel Kejzman, Günter Niegisch, David Sarid, Yuksel Urun, Yun Gyoo Lee, Oday Hamid, Alina Amalia Herzal, Michael Schenker, Eli Rosenbaum, Enrique Grande, Raya Leibowitz-Amit, Naoto Miyajima, Michiel S. van der Heijden, Shinichi Yamashita, Susanna Yee Shan Cheng, Kazuo Nishimura, Sun Young Rha, Thomas Powles, Hasan Şenol Coşkun, Jens Bedke, Ivor J. Percent, Christos Papandreou, James K. Schwarz, Masafumi Oyama, Giorgio V. Scagliotti, Chong-Xian Pan, Yoshihiko Tomita, Giampaolo Tortora, Stéphane Culine, Suet Lai Shirley Wong, Andrey Semenov, Jennifer L. Cultrera, Niels Viggo Jensen, Michael Stöckle, Katsuyoshi Hashine
المساهمون: Medical Oncology, UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Unité d'oncologie médicale, UCL - (SLuc) Centre du cancer, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Interne Geneeskunde, MUMC+: MA Medische Oncologie (9), Petrylak, Dp, de Wit, R, Chi, Kn, Drakaki, A, Sternberg, Cn, Nishiyama, H, Castellano, D, Hussain, Sa, Flechon, A, Bamias, A, Yu, Ey, van der Heijden, M, Matsubara, N, Alekseev, B, Necchi, A, Geczi, L, Ou, Yc, Coskun, H, Su, Wp, Bedke, J, Gakis, G, Percent, Ij, Lee, Jl, Tucci, M, Semenov, A, Laestadius, F, Peer, A, Tortora, G, Safina, S, del Muro, Xg, Rodriguez-Vida, A, Cicin, I, Harputluoglu, H, Tagawa, St, Vaishampayan, U, Aragon-Ching, Jb, Hamid, O, Liepa, Am, Wijayawardana, S, Russo, F, Walgren, Ra, Zimmermann, Ah, Hozak, Rr, Bell-McGuinn, Km, Powles, T, Graduate School
المصدر: Lancet Oncology, 21(1), 105-120. Lancet Publishing Group
The Lancet. Oncology, Vol. 21, no.1, p. 105-120 (2020)
Lancet oncology, 21(1), 105-120. Elsevier Science
lancet oncology, 21(1), 105-120. Lancet Publishing Groupمصطلحات موضوعية: Male, 0301 basic medicine, MULTICENTER, Docetaxel, Gastroenterology, ANGIOGENESIS, VINFLUNINE, 0302 clinical medicine, Antineoplastic Combined Chemotherapy Protocols, Clinical endpoint, Neoplasm Metastasis, education.field_of_study, CHEMOTHERAPY, Middle Aged, OPEN-LABEL, Prognosis, Survival Rate, Oncology, 030220 oncology & carcinogenesis, Female, medicine.drug, EXPRESSION, Urologic Neoplasms, medicine.medical_specialty, BEVACIZUMAB, Population, BLADDER-CANCER, Neutropenia, Antibodies, Monoclonal, Humanized, Placebo, Ramucirumab, 03 medical and health sciences, Double-Blind Method, Internal medicine, medicine, Humans, Neoplasm Invasiveness, education, Survival rate, Aged, Platinum, Salvage Therapy, Carcinoma, Transitional Cell, business.industry, medicine.disease, ATEZOLIZUMAB, 030104 developmental biology, ENDOTHELIAL GROWTH-FACTOR, business, Febrile neutropenia, Follow-Up Studies
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf61e6c114a1ba3c5764d0e77ad9425aTest
https://doi.org/10.1016/s1470-2045Test(19)30668-0 -
3
المؤلفون: Xieyang Jia, Christopher J. Hoimes, Eric Sbar, Neal D. Shore, Xiao Fang, Arlene O. Siefker-Radtke, J. Alfred Witjes, Hiroyuki Nishiyama, Ritesh S. Kataria, Andrea Necchi, Gary D. Steinberg, Matthew D. Galsky, Jens Bedke
المساهمون: Galsky, M. D., Hoimes, C. J., Necchi, A., Shore, N., Witjes, J. A., Steinberg, G., Bedke, J., Nishiyama, H., Fang, X., Kataria, R., Sbar, E., Jia, X., Siefker-Radtke, A.
المصدر: Future Oncology, 17, 24, pp. 3137-3150
Future Oncology, 17, 3137-3150مصطلحات موضوعية: 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, Combination therapy, medicine.medical_treatment, Pembrolizumab, Antibodies, Monoclonal, Humanized, Programmed death 1, Placebo, Cystectomy, 03 medical and health sciences, Antineoplastic Agents, Immunological, 0302 clinical medicine, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Urological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15], medicine, Humans, Perioperative, Antibody-drug conjugate, Carcinoma, Transitional Cell, Chemotherapy, Bladder cancer, business.industry, General Medicine, medicine.disease, Neoadjuvant Therapy, Clinical trial, Radical cystectomy, 030104 developmental biology, Urinary Bladder Neoplasms, 030220 oncology & carcinogenesis, Nectin-4, Immunotherapy, business, Muscle-invasive bladder cancer
وصف الملف: application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8bd766c10f490958ee1800a7f90217adTest
-
4
المؤلفون: Xiaotao Qu, Jens Bedke, Daniel A. Vaena, Sergio Bracarda, Alex Azrilevich, Chikara Ohyama, Padmanee Sharma, Alexandre Lambert, Marc-Oliver Grimm, Sumanta K. Pal, Jose Angel Arranz, Elizabeth R. Plimack, Ari David Baron, Margitta Retz, Matthew D. Galsky, Arlene O. Siefker-Radtke, Andrea Necchi, Abdel Saci, Suba Krishnan
المساهمون: Sharma, P, Retz, M, Siefker-Radtke, A, Baron, A, Necchi, A, Bedke, J, Plimack, Er, Vaena, D, Grimm, Mo, Bracarda, S, Arranz, Ja, Pal, S, Ohyama, C, Saci, A, Qu, Xt, Lambert, A, Krishnan, S, Azrilevich, A, Galsky, Md
المصدر: The Lancet Oncology. 18:312-322
مصطلحات موضوعية: Adult, Male, 0301 basic medicine, Urologic Neoplasms, medicine.medical_specialty, Metastatic Urothelial Carcinoma, Antineoplastic Agents, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Carcinoma, medicine, Clinical endpoint, Humans, Neoplasm Metastasis, Survival rate, Aged, Neoplasm Staging, Platinum, Aged, 80 and over, Carcinoma, Transitional Cell, business.industry, Antibodies, Monoclonal, Middle Aged, Prognosis, medicine.disease, Chemotherapy regimen, Surgery, Survival Rate, Clinical trial, Nivolumab, 030104 developmental biology, Oncology, Drug Resistance, Neoplasm, Response Evaluation Criteria in Solid Tumors, 030220 oncology & carcinogenesis, Female, Neoplasm Recurrence, Local, business, Follow-Up Studies
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3533e8ebeded2ae036638e06e08971dcTest
https://doi.org/10.1016/s1470-2045Test(17)30065-7